内科

目的评估重组人B型利钠肽（rhBNP）治疗慢性心力衰竭急性发作失代偿期患者的临床疗效。方法将44例急性失代偿期慢性心力衰竭（ADCHF）患者随机分为rhBNP组（23例）和常规治疗组（21例），两组均给予利尿、吸氧等常规治疗，rhBNP组在此基础上给予rhBNP，观察并比较两组患者的临床疗效、心功能指标及不良反应情况。结果rhBNP组患者疗效优于常规治疗组，两组比较差异有统计学意义（P＜0.05）。治疗2周后，rhBNP组患者BNP显著低于常规治疗组，比较差异具有统计学意义（P＜0.05）；两组患者LVEDD比较差异无统计学意义（P＞0.05），但LVEF比较差异有统计学意义（P＜0.05）。rhBNP组不良反应发生率为13.04%，显著低于常规治疗组的33.33%（P＜0.05）。结论rhBNP能显著改善ADCHF患者的心功能，增加心输出量，临床疗效确切，不良反应发生率低。

ObjectiveTo explore the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) in treatment of acute decompensated of chronic heart failure(ADCHF). Methods44 patients with ADCHF were randomly divided into rhBNP group (23 cases) and conventional therapy group (21 cases), both groups were treated with conventional therapy, including dieresis,oxygen,etc, and the rhBNP group were given rhBNP, clinical efficacy, the cardiac function index and adverse effect were observed and compared. ResultsThe effect of observation group was significantly better than that of control group (P＜0.05). After treatment for 2 weeks, the BNP in the rhBNP group was significantly lower than that of conventional therapy group (P＜0.05); there was no significant difference in LVEDD between two groups（P＞0.05）, but LVEF between two groups had significant difference(P＜0.05). The adverse reaction rate of rhBNP group was 13.0%，which was significantly lower than that of conventional therapy group (38.1%) (P＜0.05). ConclusionsrhBNP can improve cardiac function, increase cardiac output for ADCHF patients, with lower adverse reaction rate,the clinical efficacy is exact.

ref